John Fallon left the role of Director at Collegium Pharmaceutical, Inc. As of November 6, 2026, Collegium Pharmaceutical, Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 7, 2026 to May 12, 2026, naming 1 departure (Form 8-K, April 7, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Collegium Pharmaceutical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Collegium Pharmaceutical, Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-07 to 2026-05-12. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Collegium Pharmaceutical, Inc files it.
Also on the record for Collegium Pharmaceutical, Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G/A, by Vanguard Capital Management | 4.97% of the class | 5%+ stakes | Source |
| October 29, 2026 | Stake report, Schedule 13G/A, by PRINCIPAL GLOBAL INVESTORS | 4.7% of the class | 5%+ stakes | Source |
| October 8, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 7.4% of the class | 5%+ stakes | Source |
| August 24, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 5.6% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Fuller & Thaler Asset Management, Inc. | 5.03% of the class | 5%+ stakes | Source |
| August 5, 2026 | Stake report, Schedule 13G, by PRINCIPAL GLOBAL INVESTORS | 5% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.01% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 5.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Eventide Asset Management, LLC | 4.5% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 4.53% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by Integrated Core Strategies (US) LLC | 4.7% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G, by Invesco Ltd. | 5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Collegium Pharmaceutical, Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Collegium Pharmaceutical, Inc and the records around it.
Collegium Pharmaceutical, Inc elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Ovid Therapeutics Inc. (Aug 2026), Beta Bionics, Inc. (May 2026)
- PRINCIPAL GLOBAL INVESTORS also filed stake reports on 19 other companies: Brookfield Infrastructure Partners L.P. (Oct 2026), Hyatt Hotels Corp (Oct 2026), National Healthcare Properties, Inc. (Oct 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
Watch Collegium Pharmaceutical, Inc
Get an email when Collegium Pharmaceutical, Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Collegium Pharmaceutical, Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Collegium Pharmaceutical, Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Collegium Pharmaceutical, Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 19 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-12 | Reported | not named in the filing | 8-K, 2026-05-12 | ||
| 2026-04-07 | Out | Director | 8-K, 2026-04-07 |
Who leads Collegium Pharmaceutical, Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: John Fallon, departure reported (filed 2026-04-07). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Collegium Pharmaceutical, Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Collegium Pharmaceutical, Inc, with the record behind each one.
Find candidates like Director at Collegium Pharmaceutical, IncEvery change, in the filing's words
Reported
Leadership Changes On May 11, 2026, the Company announced that Scott Dreyer, Executive Vice President and Chief Commercial Officer of the Company will depart from his positions at the Company effective August 30, 2026.
- 2026 Inducement Plan On May 11, 2026, the Company's board of directors adopted the Company's 2026 Inducement Plan (the "Inducement Plan"), pursuant to which the Company may grant non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, and dividend equivalent rights with respect to an aggregate of 325,000 shares of the Company's common stock, par value $0.001 per share.
- Awards under the Inducement Plan may only be granted to new employees who were not previously an employee or director of the Company or are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to the individual's entering into employment with the Company.
- In accordance with Nasdaq Listing Rule 5635(c)(4), the Company did not seek approval of the Inducement Plan by its stockholders.
- Mr. Dreyer's departure will be treated as a termination without cause pursuant to the terms of his existing employment agreement with the Company.
- On May 11, 2026, the Company also announced that Thomas Smith, M.D., Executive Vice President and Chief Medical Officer of the Company will depart from his positions at the Company following a transition period during which the Company will conduct a search for his successor.
Departing: John Fallon, Director
Director Retirement On April 2, 2026, John Fallon, M.D., a current member of the Board, advised the Board that he will not stand for re-election at the Annual Meeting and will retire from the Board at that time.
- Departure of Directors or Principal Officers; Election of Directors Director Nominee On April 6, 2026, the board of directors ("Board") of Collegium Pharmaceutical, Inc. (the "Company") approved the nomination of Michael Donovan to stand for election at the Company's 2026 Annual Meeting of Shareholders (the "Annual Meeting").
- Mr. Donovan, 60, has served as an audit Partner at Ernst & Young LLP ("EY") since 2002.
- He has held several leadership roles at EY including Office Managing Partner of EY's biotechnology office in Kendall Square from 2014 to 2024 and East Region Biotechnology Leader.
- Mr. Donovan brings to our Board financial expertise obtained from his extensive business, accounting and financial background from over 36 years of experience serving public and private companies in the life sciences industry.
- During his tenure at EY, he has worked on hundreds of private and public company audits, private and public financings including IPOs, M&A transactions, corporate license and collaboration agreements, spin-outs and product launches.
- Mr. Donovan received a B.S. in Business Administration from Merrimack College and is a Certified Public Accountant (active).
- Dr. Fallon has served as a director since 2016, and he will continue as a director until the Annual Meeting.
Tools for this story
Each opens in a new tab, filled in for Collegium Pharmaceutical, Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.